A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Abstract Introduction Components of the hedgehog signaling pathway are upregulated in patients with idiopathic pulmonary fibrosis (IPF). Vismodegib, a small-molecule inhibitor of hedgehog signaling, when used in combination with currently available antifibrotic therapy, may be more efficacious than...

Full description

Bibliographic Details
Main Authors: Antje Prasse, Murali Ramaswamy, Shaun Mohan, Lin Pan, Andrew Kenwright, Margaret Neighbors, Paula Belloni, Peter P. LaCamera
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-07-01
Series:Pulmonary Therapy
Subjects:
Hedgehog signaling pathway
Idiopathic pulmonary fibrosis
Pirfenidone
Safety
Tolerability
Vismodegib
Online Access:http://link.springer.com/article/10.1007/s41030-019-0096-8

Internet

http://link.springer.com/article/10.1007/s41030-019-0096-8

Similar Items